The Registry Study of Takayasu Arteritis in East China
NCT03893136
·
clinicaltrials.gov ↗
RECRUITING
Status
1000
Enrollment
OTHER
Sponsor class
Conditions
Takayasu Arteritis
Mechanisms, Defense
Pregnancy Related
Treatment Refusal
Outcome
Interventions
BIOLOGICAL:
Tocilizumab
DRUG:
Leflunomide
Sponsor
Shanghai Zhongshan Hospital